NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference
18 déc. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace to Host Investor Day on January 28th in New York City
12 déc. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting
04 déc. 2024 16h05 HE
|
NeuroPace, Inc.
RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the...
NeuroPace Completes Enrollment in Feasibility Study of RNS System for Lennox-Gastaut Syndrome
03 déc. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy,...
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
12 nov. 2024 16h05 HE
|
NeuroPace, Inc.
-- Grew revenue 28% year-over-year to $21.1 million in Q3 2024 -- -- Increased full-year 2024 revenue guidance to $78 million to $80 million -- -- Demonstrated continued operating discipline through...
NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy
04 nov. 2024 16h05 HE
|
NeuroPace, Inc.
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug-resistant focal epilepsy The RNS System PAS evaluates safety and...
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
22 oct. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...
NeuroPace Continues to Strengthen Management Team
16 oct. 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced...
NeuroPace Strengthens Management Team with Two Key Appointments
04 sept. 2024 16h05 HE
|
NeuroPace, Inc.
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific’s DBS franchise as the new Vice...
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
27 août 2024 16h05 HE
|
NeuroPace, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it...